1-4 of 4
Melannie Co
Close
Sort by
Journal Articles

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Jake Shortt, Pau Montesinos, Shuh Ying Tan, Teng Fong Ng, Chun Yew Fong, Paul Cannell, Rajeev Rajagopal, Sophia Leitch, Peter T. Tan, Sundra Ramanathan, Robin Gasiorowski, Douglas Stuart Lenton, Tse-Chieh Teh, José Antonio Pérez-Simón, Carolyn Grove, Xiaojun Huang, Courtney D. DiNardo, Katherine Naidu, Joseph Pariseau, Si Cheng, Yu Liu, Melannie Co, Wai Y. Chan, Haiyi Guo, Andrew H. Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 3329–3332.
https://doi.org/10.1182/blood-2022-166937
Published: 2022
Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M. Linton, Pamela McKay, Henry Chan, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Peter J. Browett, Xiaoyan Ke, Craig A. Portell, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza Hawkes, Shir-Jing Ho, Keshu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Journal: Blood
Blood (2022) 140 (Supplement 1): 573–576.
https://doi.org/10.1182/blood-2022-163371
Published: 2022
Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Stephen Opat, FRACP, FRCPA, MBBS, Alessandra Tedeschi, MD, Kim Linton, MBChB, MRCP, PhD, Pamela McKay, MBChB (Hons), FRCP, FRCPath, Bei Hu, MD, Henry Chan, MBChB, FRACP, FRCPA, Jie Jin, MD PhD, Pier Luigi Zinzani, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA, Morton Coleman, MD, Magdalena Sobieraj-Teague, MBBS, FRACP, FRCPA, M.Sc, Xiaoyan Ke, MD PhD, Mingyuan Sun, MD, Robert Marcus, MA, FRCP, FRCPath, Craig A. Portell, MD, Keshu Zhou, MD PhD, Catherine Thieblemont, MD PhD, Melannie Co, MD, Weige Wang, MD, Chris Tankersley, BS, Wenxiao Zhou, M.Sc, Massimo Cappellini, BS, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–30.
https://doi.org/10.1182/blood-2020-134611
Published: 2020
Journal Articles

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Radhakrishnan Ramchandren, MD, Peter Johnson, MD, Nilanjan Ghosh, MD PhD, Jia Ruan, MD PhD, Kirit M. Ardeshna, MA MDFRCP FRCPath, Roderick Johnson, MD, Gregor Verhoef, MD PhD, David Cunningham, Sven de Vos, Shireen Kassam, MD, Luis Fayad, MD, John Radford, MD FRCP, Sarah Bailly, MD, Fritz Offner, MD, David Morgan, MD, Javier Munoz, MD, Jerry Ping, PhD, Melannie Co, MD BSMedTech, BSN, Jutta K. Neuenburg, MD PhD, Andre Goy, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 402.
https://doi.org/10.1182/blood-2018-99-111163
Published: 2018